Welcome to our dedicated page for Voyager Therapeutics news (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company focused on leveraging genetics to treat neurological diseases, and its news flow reflects progress across a multi-modality pipeline. Press releases frequently highlight updates in Alzheimer’s disease programs, including the anti-tau antibody VY7523 and the tau silencing gene therapy VY1706, as well as broader work in Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and other central nervous system conditions.
News items cover clinical and preclinical data presentations at scientific meetings such as the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) and the American Society of Gene & Cell Therapy (ASGCT) annual meeting. Voyager reports new non-human primate and murine data, details on tau and amyloid targeting strategies, and advances in its TRACER™ AAV capsid discovery platform and next-generation capsids designed for blood-brain barrier penetration and immune evasion.
Investors and followers of VYGR can also expect regular financial and operating updates, typically furnished via Form 8-K, that summarize quarterly collaboration revenue, research and development spending, and cash position, along with commentary on cash runway and partnered program milestones. Additional news addresses collaborations and partnerships, including agreements with Neurocrine Biosciences, Novartis Pharma AG, Alexion, AstraZeneca Rare Disease, and a small molecule collaboration and option agreement with Transition Bio targeting TDP-43 in ALS and frontotemporal dementia.
This news page aggregates Voyager’s corporate announcements, scientific data disclosures, partnership updates, and financial reports, providing a centralized view of developments that may influence the company’s therapeutic pipeline and platform evolution. Readers interested in VYGR stock and the company’s role in genetic medicines for neurological disease can use this feed to follow key milestones and scientific progress over time.
Voyager Therapeutics (Nasdaq: VYGR), a gene therapy innovator, has announced its participation in two upcoming virtual investor conferences. The company will present at the SVB Leerink 11th Annual Global Healthcare Conference on Feb. 18, 2022, at 9:20 a.m. ET, and participate in a corporate panel at the Cowen 42nd Annual Health Care Conference on Mar. 9, 2022, at 12:50 p.m. ET. Investors can access the sessions on Voyager's website and replays will be available for at least 30 days.
Voyager Therapeutics (Nasdaq: VYGR) announced the appointment of Alfred W. Sandrock, Jr. to its Board of Directors and the promotion of Robin Swartz to Chief Operating Officer, effective February 7, 2022. Dr. Sandrock, a seasoned drug developer with extensive experience at Biogen, will help steer Voyager's strategies for its TRACER™ AAV capsid screening platform and foster collaborations. Ms. Swartz will oversee several operational departments, marking a strategic leadership change aimed at enhancing the company's gene therapy initiatives.
Voyager Therapeutics (Nasdaq: VYGR) has presented preclinical data showing that its proprietary AAV vector, developed using TRACER™ technology, effectively targets HER2+ breast cancer brain metastases. The findings indicate that intravenous dosing of this vector leads to significant tumor reduction and improved survival rates in mouse models. The anti-HER2 antibody produced through this method achieves high concentrations in cerebrospinal fluid, suggesting potential for effective treatment against CNS tumors. Voyager plans to continue optimizing this innovative gene therapy approach.
Voyager Therapeutics (Nasdaq: VYGR) announced the presentation of preclinical data from its vectorized antibody program at the 26th Annual Society for Neuro-Oncology Meeting on Nov. 19, 2021. The presentation, titled AAV mediated brain delivery of an ADCC-enhanced antibody obviates xenograft growth in mouse models of HER2+ breast cancer brain metastasis, will be delivered by Dan R. Laks, Ph.D., at 4:15 p.m. ET. This represents a significant advancement in the development of AAV gene therapy technology, aiming to treat severe diseases through innovative approaches.
Voyager Therapeutics has partnered with Pfizer through a licensing agreement to access its TRACER™ capsids for gene therapies targeting neurological and cardiovascular diseases. The deal includes a $30M upfront payment and potential milestone payments of up to $600M. Preclinical results from Voyager's GBA1 gene therapy indicate significant CNS distribution and enzyme activity correction. For Q3 2021, Voyager reported a net loss of $25.1M, down from a net income of $85.6M in Q3 2020, with collaboration revenue decreasing from $117.8M to $1.5M.
Voyager Therapeutics (Nasdaq: VYGR) announced promising preclinical data on its GBA1 gene replacement therapy, showing sustained correction of GCase enzyme activity across multiple brain regions in mice after a single intravenous dose. Results from the virtual Congress of the European Society of Gene and Cell Therapy indicated a 300% to 660% increase in GCase levels, potentially enabling effective treatment for neurological diseases like Gaucher disease and Parkinson’s. The therapy was well-tolerated, showcasing the advantages of blood-brain barrier-penetrant AAV capsids over traditional delivery methods.
Voyager Therapeutics (Nasdaq: VYGR) has entered a partnership with Pfizer, receiving $30 million upfront. The collaboration allows Pfizer to access Voyager's advanced AAV capsids, enhancing drug delivery for gene therapies targeting neurological and cardiovascular diseases. The agreement includes potential exercise fees and milestone payments up to $600 million, along with royalties based on product sales. Voyager retains rights for other applications of its TRACER technology, expected to boost the development of gene therapies and address unmet medical needs.
Voyager Therapeutics (Nasdaq: VYGR) announced its participation in three upcoming virtual investor conferences on September 9, 14, and 15, 2021. These conferences will feature a fireside chat at the Wells Fargo Securities Healthcare Conference, a fireside chat at the Morgan Stanley Global Healthcare Conference, and a company presentation at the Baird Global Healthcare Conference, respectively. Investors can access these sessions via the Investors & Media section of Voyager's website, where replays will also be archived for at least 30 days.
Voyager Therapeutics (Nasdaq: VYGR) announced its participation in two upcoming virtual investor conferences. The first is the Wedbush PacGrow Healthcare Conference, featuring a panel discussion on August 11, 2021, at 8:35 AM ET. The second is the Canaccord Genuity Growth Conference, which includes a fireside chat on August 12, 2021, from 10:30 to 10:55 AM ET. Investors can access these sessions via the Investors & Media section of Voyager’s website. The company focuses on advancing AAV gene therapy to treat serious diseases using its TRACER™ screening platform.
Voyager Therapeutics (VYGR) announced significant updates in its pipeline, focusing on second-generation programs for Huntington’s disease, ALS, spinal muscular atrophy, and GBA1 mutation-related diseases, utilizing proprietary AAV capsids. The TRACER platform aims to discover targeted AAV capsids for various tissues. Financially, collaboration revenue dropped to $1.4 million in Q2 2021 from $28.7 million in Q2 2020, while net loss increased to $30.1 million. The company maintains a cash position of $143 million, sufficient for operations into early 2023.